UP!

ARWR $43.33   View long term graphs

Arrowhead Pharmaceuticals
Trading name
ARWR
Type
Biopharmaceutical
Headquarters Pasadena, CA
Key people

Christopher Anzalone, Ph.D., President and Chief Executive Officer Bruce Given, M.D., Chief Operating Officer

Ken Myszkowski, MBA, CPA, Chief Financial Officer
Website http://arrowheadpharma.com/

Christopher Anzalone, Ph.D., President and Chief Executive Officer Bruce Given, M.D., Chief Operating Officer

Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for Hepatitis B,the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease. The company has six products in its pipeline, in various stages of development.

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.

In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.

News

Arrowhead Pharmaceuticals, Inc. -0.21% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2021 2021-02-03 Future report Set alerts
Q4 2020 2020-11-23 Future report Set alerts
Q3 2020 2020-08-05 -0.13 -0.13
Q2 2020 2020-05-07 -0.20 -0.20
Q1 2020 2020-02-05 -0.03 -0.03
Q4 2019 2019-11-25 0.11 0.12
Q3 2019 2019-08-05 0.21 0.21
Q2 2019 2019-05-08 0.24 0.24
Q1 2019 2019-02-07 0.13 0.13
Q4 2018 2018-12-11 -0.12 -0.12

Ratings

2016-05-19 Initiated Coverage Chardan Capital Buy $12.00
2016-05-11 Reiterated Rating Jefferies Group Hold $4.75
2016-02-11 Reiterated Rating Piper Jaffray Overweight $20.00 to $13.00
2016-02-11 Reiterated Rating Piper Jaffray Cos. Overweight $20.00 to $13.00
2016-02-10 Lower Price Target Jefferies Group Hold $7.00 to $4.00
2015-09-26 Reiterated Rating Piper Jaffray Buy
2015-09-25 Boost Price Target Piper Jaffray Overweight $12.00 to $20.00
2015-08-05 Reiterated Rating RBC Capital Hold $9.00
2015-08-05 Reiterated Rating Royal Bank Of Canada Hold $9.00
2015-05-23 Reiterated Rating Jefferies Group Hold $9.00 to $7.50
2015-04-14 Downgrade Jefferies Group Buy to Hold $9.00
2015-01-22 Downgrade Deutsche Bank Buy to Hold $7.00
2015-01-22 Downgrade Deutsche Bank AG Buy to Hold $7.00
2014-10-08 Downgrade RBC Capital Outperform to Sector Perform $35.00 to $9.00
2014-10-08 Lower Price Target Deutsche Bank Buy $45.00 to $20.00
2014-09-17 Reiterated Rating RBC Capital Outperform
2014-08-13 Reiterated Rating Deutsche Bank Buy
2014-06-20 Boost Price Target Jefferies Group Buy $29.00 to $30.00
2014-05-07 Lower Price Target Jefferies Group Buy $30.00 to $29.00
2014-03-24 Reiterated Rating Deutsche Bank Buy
2014-03-05 Initiated Coverage Deutsche Bank Buy $45.00
2014-03-04 Initiated Coverage RBC Capital Buy to Outperform $45.00 to $35.00
2014-03-03 Initiated Coverage Barclays Overweight
2014-02-07 Boost Price Target Jefferies Group $15.00 to $30.00
2013-12-18 Initiated Coverage Jefferies Group Buy $15.00
2013-10-21 Initiated Coverage Piper Jaffray Overweight $12.00 to $7.87
2013-02-26 Initiated Dawson James Buy $4
2016-05-19 Initiated Coverage Chardan Capital Buy $12.00
2016-05-11 Reiterated Rating Jefferies Group Hold $4.75
2016-02-11 Reiterated Rating Piper Jaffray Overweight $20.00 to $13.00
2016-02-11 Reiterated Rating Piper Jaffray Cos. Overweight $20.00 to $13.00
2016-02-10 Lower Price Target Jefferies Group Hold $7.00 to $4.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Anzalone Christopher Richard President and CEO 3.72%  (1968789) ARWR /
GIVEN BRUCE D Chief Operating Officer 1.72%  (908356) ARWR /
Myszkowski Kenneth Allen CFO 0.59%  (310815) ARWR /
O'Brien Patrick General Counsel 0.44%  (235000) ARWR /
PERRY MICHAEL S 0.35%  (185000) APHB / ARWR / TGEN /
GIVEN DOUGLAS B 0.29%  (155000) ARWR /
FRYKMAN EDWARD W 0.28%  (148852) ACTG / ARWR /
Leone Peter Brian VP, Strategy & Program Mgmt 0.25%  (130000) ARWR /
Ferrari Mauro 0.12%  (62768) ARWR /
McKenney Charles 0.08%  (42220) ARWR /
Waddill William D. 0.05%  (25000) ARWR / CALA / OMED / PTGX /

Comments